Biovica International AB

Equities

BIOVIC B

SE0008613731

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-04-26 am EDT			5-day change	1st Jan Change
1.706 ^SEK	+6.36%		-22.81%	-33.88%

Apr. 13	Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024.	CI
Apr. 12	Biovica International AB Announces Divitum® Tka in Observational Trial	CI

Biovica International Signs Provider Contract with Provider Network Contigo Health ConfigureNet

June 10, 2023 at 06:55 am EDT

Biovica International announced that it has signed a provider contract with Contigo Health ConfigureNet provider network. This commercial agreement will make Biovica's blood test, DiviTum TKa, available to clients and their health plan members served by clients of Contigo Health.

Latest news about Biovica International AB

Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024.	Apr. 12	CI
Biovica International AB Announces Divitum® Tka in Observational Trial	Apr. 12	CI
Biovica International AB Announces Appointments to the Nomination Committee	Apr. 11	CI
Transcript : Biovica International AB, Q3 2024 Earnings Call, Mar 14, 2024	Mar. 14
Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 14	CI
Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University	Mar. 13	CI
Biovica International Signs SEK 1.2 Million Master Service Agreement	Mar. 12	CI
Biovica Signs Master Service Agreement for Tka Testing with Leading Pharma Company	Mar. 07	CI
Biovica Partners with Palex Group to Launch Breast Cancer Treatment Response Kits; Stock Surges	Jan. 19	MT
Biovica International Signs Agreement with Palex Group	Jan. 19	CI
Biovica Receives License for Maryland State	Dec. 01	CI
Transcript : Biovica International AB, Q2 2024 Earnings Call, Nov 28, 2023	Nov. 28
Biovica International AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Nov. 28	CI
Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare	Nov. 21	CI
Biovica Signs Commercial Partner Agreement for the Divitum(R) Tka Assay in the Nordics with Axlab	Nov. 13	CI
Biovica International AB Signs Agreement for DivTum(R) TKa with World Re-Known Cancer Clinic	23-10-12	CI
Biovica Signs Second Agreement with US Healthcare Provider	23-09-25	CI
Biovica Signs US Agreement with Leading Healthcare Provider in Arizona	23-09-19	CI
Transcript : Biovica International AB, Q1 2024 Earnings Call, Sep 06, 2023	23-09-06
Biovica International AB Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-06	CI
Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial	23-08-24	CI
Biovica Lands US Commercial Deal for DiviTum TKa Blood Tests, Shares Jump 15%	23-07-31	MT
Biovica Signs US Commercial Agreement with Occum Health	23-07-31	CI
Biovica International Achieves PLA code for Medicare	23-07-21	CI
Transcript : Biovica International AB, Q4 2023 Earnings Call, Jun 21, 2023	23-06-21

Chart Biovica International AB

Duration

Period

More charts

Company Profile

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Sector

Biotechnology & Medical Research

Calendar

2024-06-17 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Biovica International AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.706 SEK

Average target price

15 SEK

Spread / Average Target

+779.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
BIOVICA INTERNATIONAL AB	-33.88%	13.08M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M

Bio Diagnostics & Testing